CFO4Life Group LLC raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 5.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,326 shares of the biopharmaceutical company’s stock after purchasing an additional 222 shares during the quarter. CFO4Life Group LLC’s holdings in Celgene Corporation were worth $562,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Celgene Corporation during the 1st quarter valued at approximately $118,000. Penserra Capital Management LLC acquired a new stake in Celgene Corporation during the 2nd quarter valued at approximately $129,000. Acropolis Investment Management LLC acquired a new stake in Celgene Corporation during the 2nd quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the period. Finally, Rational Advisors LLC acquired a new stake in Celgene Corporation during the 2nd quarter valued at approximately $156,000. 79.39% of the stock is owned by institutional investors and hedge funds.
A number of research firms have weighed in on CELG. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Thursday, October 5th. Royal Bank Of Canada reissued a “buy” rating and set a $173.00 target price on shares of Celgene Corporation in a research report on Thursday, October 5th. Robert W. Baird reissued a “buy” rating and set a $162.00 target price on shares of Celgene Corporation in a research report on Thursday, September 21st. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 target price on shares of Celgene Corporation in a research report on Tuesday, September 26th. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation has an average rating of “Buy” and an average target price of $139.64.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.58 earnings per share.
In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,733 shares of company stock worth $5,259,359. Corporate insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/11/02/cfo4life-group-llc-purchases-222-shares-of-celgene-corporation-celg.html.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.